The anti-tumor action of EGCG has been confirmed in numerous in vitro experiments or in animal studies in which the interactions of EGCG with the above-mentioned cell surface receptors [70,84,87,89,90,91,92,93,94,96] and, subsequently, with intracellular signaling pathways [70,100,101,103,104,107,108] and nuclear transcription factors [80,103,118,122,125,126,130,131,136] have been shown (Table 1). The gene discussed is CD177; the disease is neoplasm.